然而已有机制研究提出奥美拉唑会降低氯吡格雷抗血小板的疗效。
Recent mechanistic studies, however, suggest that omeprazole may reduce the inhibitory effect of clopidogrel on platelet aggregation.
在发生晚期和极晚期ST的患者中，双重抗血小板的应用比例分别占57%和36%。
Among those with late and very late ST, the prevalence of dual-antiplatelet therapy was 57% and 36%, respectively.
还具有改善微循环、抗血小板的聚集和血栓形成，并能使血液粘度下降，改善血液循环。
And have improvement microcirculation, resist blood platelet aggregation and thrombopoiesis, can make blood viscosity come down, improve blood circulation.
有一种方法是注射可溶性CD39，但是会和阿司匹林或氯吡格雷一样存在抗血小板的副作用。
One way is to infuse a soluble form of CD39 which could have some side effects according to all the antiplatelet therapies like aspirin or clopidogrel.
CD39可以磷酸化水解ATP成ADP，而ADP是血小板激活和聚集的主要激动剂，所以CD39具有抗血小板的作用。
CD39 is phosphohydrolysing ATP and ADP, noting that ADP is the major agonist for platelet activation and aggregation, so CD39 has a pretty similar mechanism to antiplatelet therapies.
销毁发生在免疫介导的血小板减少，其中血小板被抗血小板抗体包被，并由吞噬细胞从循环系统中清除。
Destruction occurs in immune-mediated thrombocytopenia, in which platelets become coated with antiplatelet antibodies and are removed from the circulation by the fixed phagocyte system.
研究者们指出“纳米粒子是一种极具潜力的抗血小板聚集制剂”。
The nanoparticles "hold immense potential to be promoted as an antiplatelet agent," the researchers note.
幽门螺杆菌阳性的病人也是要关注的对象，还有那些服用非甾体消炎药的同时还服用血液稀释剂(例如华法令阻凝剂或者抗血小板药物)或甾类化合物的人。
Patients who are H. pylori positive are also at high risk, as are those who take Nsaids while also taking blood thinners (such as warfarin or antiplatelet drugs) or steroids.
但是这些抗血小板药物也增加出血的风险，包括上消化道出血。
But these antiplatelet drugs also increase the risk of bleeding, including upper GI bleeding.
阿司匹林还是唯一的一个有证据支持其在急性脑卒中使用的抗血小板药。其它的药物还在试验中。
Aspirin remains the only antiplatelet agent for which data support use in acute stroke, although trials with other agents are in progress.
但是近期的报道已经表明两种药物之间有潜在危险的相互作用，由此质子泵抑制剂降低抗血小板药物的实际效果。
But recent reports had suggested that there might be a potentially dangerous interaction between the two drug classes whereby PPIs reduce the actual effectiveness of antiplatelet agents.
现在专家的一致意见认为，这可能是由于抗血小板和抗血栓治疗不足所引起的。
And there's consensus that the increased ischemic events are related to insufficient antiplatelet and antithrombotic therapy.
这些结果都强调了对于糖尿病患者抗血小板治疗方案的个体化需要。
These findings underscore the need of individualized antiplatelet treatment regimens in diabetic patients.
接受药物洗脱支架的患者长病变和复杂病变比接受裸金属支架的患者多，而且接受双重抗血小板治疗1年的可能性较大。
DES recipients had longer and more complex lesions than BMS recipients and also were more likely to be receiving dual antiplatelet therapy at 1 year.
没有任何证据表明，抗血小板制剂降低心衰患者动脉粥样硬化的危险。
There is no evidence that antiplatelet agents reduce atherosclerotic risk in patients with HF.
现在ACTIVEA结果加入到我们对于强效抗血小板治疗在选择性预防房颤病人卒中作用的理解中。
ACTIVE a now adds to our understanding of the role of intensive antiplatelet therapy to prevent stroke in selected patients with atrial fibrillation.
背景：氯吡格雷是一种导致凝血时间延长的抗血小板药物。
Background: Clopidogrel is an anti-platelet agent which causes an increase in bleeding time.
不同的抗血小板药物对PLA形成的影响有所差异，监测pla有助于指导抗血小板药的临床应用和筛选。
The PLA formation is affected variously by various antiplatelet agents. Monitoring of PLA formation is helpful in guiding the clinical use and selection of antiplatelet agents.
文章主要探讨抗血小板药的临床应用、最佳剂量以及抗血小板药与其他干预手段的联合应用。
This article mainly discusses the clinical application and optimal dosage of the antiplatelet agent and its combination with other interventions.
目的：观察舒心饮与抗血小板药物联合应用对冠状动脉支架血栓等术后冠脉事件的预防作用。
Objective: To evaluate the preventive effect of antiplatelet regimens and it′s combination with Shuxinyin (SXY) on coronary events including stent thrombosis after stenting implantation.
我觉得，三重治疗并不能解决问题，而应该选择其他可选择的抗血小板药物。
In my opinion, it is not with triple therapy that we can solve this problem but with alternative antiplatelet agents.
抗血小板药物(例如波利维)被用来帮助预防伴心脏病人群中潜在有危险性的血栓形成。
Antiplatelet drugs, such as Plavix, are used to help prevent potentially dangerous blood clots from forming in people with heart disease.
双重抗血小板治疗的最佳持续时间取决于特定心脏指征(见本增刊中其他篇目)。
The optimal duration of dual antiplatelet therapy depends on the specific cardiac indication (see other articles in this supplement) for recommended for specific indications.
本文介绍了常用抗血小板药物的作用机制以及指南性建议和临床试验证据。
This article introduces the mechanism of currently available antiplatelet drugs as well as their practice guidelines and evidence from clinical trials.
《国际循环》：慢性肾功能不全的患者抗血小板治疗的实施方法与ACS患者有何差别？
International Circulation: For the patients with chronic renal function failure, is there any difference from other patients with ACS in the management of antiplatelet therapy?
《国际循环》：慢性肾功能不全的患者抗血小板治疗的实施方法与ACS患者有何差别？
International Circulation: For the patients with chronic renal function failure, is there any difference from other patients with ACS in the management of antiplatelet therapy?
应用推荐